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Summary 
The clinical history before transplantation and subsequent clinical and biochemical course of 3 chim'ren and 
one adult with hereditary tyrosinemia treated by orthotopic hepatic transplantation is described. All four pa-
tients are now free of their previous dietary restrictions and appear to be cured of both their metabolic disease 
and their hepatic neoplasm. 
Introduction 
Hereditary tyrosinemia is an inborn error of tyro-
sine metabolism which results from a deficiency of 
the enzyme, fumarylacetoacetate hydrolase [1-6]. A 
pathognomic feature of the disease is the presence of 
succinyl acetone (4,6-dioxoheptonic acid) in the se-
rum and urine of affected persons. It is characterized 
by multiple proximal renal tubular defects, including 
a decreased capacity to reabsorb phosphate which 
leads to rickets, and progressive hepatic fibrosis lead-
ing to cirrhosis and hepatoma [1,5-10]. Intermit-
tant extreme elevations of alpha-fetoprotein occur 
in all patients with the disease. To date, with 
the exception of a single patient, the clinical manage-
ment of children with this disorder has been limited 
to dietary manipulation [7,11-14]. We have per-
formed orthotopic hepatic transplantation in 4 
patients with tyrosinemia, 3 children and 1 adult, 
who had developed hepatic neoplasms. The present 
communication is a report of the biochemical find-
ings and clinical course before and after transplanta-
tion in these four patients. 
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em!' pre\entations 
Patient 1 
LT is a 41/2-year-old girl who was referred because 
of hepatic failure, ascites, Fanconi's syndrome, a 
biopsy-proven hepatoma with an alpha-fetoprotein 
level of 182 000 ng/ml and failure to thrive. Devel-
opmental milestones had occurred normally until 6 
months of age, but she was not standing or making 
sounds at 13 months of age. At 9 months of age, her 
hemoglobin was 12.5 g/dl. At 1 year it was 10.5 at 
which time her spleen was noted to be enlarged. At 
18 months she was at the 25th percentile in weight 
and 50th percentile for height and had a head circum-
ference at the 15th percentile. In addition her liver 
was enlarged and the spleen was enlarged 2 em below 
the left costal margin. Neurologic evaluation re-
vealed poor levels of proximal muscle strength in the 
lower extremities, Plasma tyrosine (751.uM; nl = 21-
ff7 ,uM), methionine (989 ,uM; nl = 6-39 ,uM), and 
ammonia (9.4 mM; nl < 40 mM) were all elevated. 
Similarly urinary threonine, serine, glycine, alanine, 
methionine, isoleucine and tyrosine were increased 
(data not shown). No response to glycogen was ob-
served either fasting or post praidially and galactose-
I-phosphate uridyltransferase activity was within 
normal limits. The serum alpha-fetoprotein level was 
increased markedly at 182 000 ng/l. Recurrent epi-
sodes of hypoglycemia and acidosis were prominent 
clinical problems. Liver biopsy showed cirrhosis with 
nodular arcas with variable amounts of steatosis. The 
hepatic enzymes of tyrosine metabolism measured in 
the liver included: tyrosine amino transferase (0,024 
units/mg protein, nl = MKMOT~MKM91F; 4 hydroxyphe-
nylpyruvate di-oxygenase «0.004 units/mg protein; 
nl = 0.085-0.144); and fumararyl acetoacetate hy-
dralase (0.15 units/mg protein; nl = 0.60-1.17). A 
diagnosis of hereditary tyrosinenemia was made and 
she was placed on a severely restricted tyrosine-free 
diet. 
She had been followed prospectively with serial 
abdominal ultrasound examinations at quarterly in-
tervals and 4 months prior to transplantation several 
new hepatic defects consistent with hepatoma were 
detected. Pertinent laboratory data are shown in 
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Table 1. She underwent orthotopic hepatic trans-
plantation on 11 November, 1981. The liver was 
found to contain numerous small hepatomas measur-
ing 3-5 cm in diameter, Postoperatively she did well 
until early 1983 when her serum bilirubin level in-
creased slightly and hepatic rejection was diagnosed. 
She failed to respond to increased immunosuppres-
sion and underwent a second liver transplant on 13 
May, 1983. She has been well and eating an unre-
stricted diet for 31 months following her second 
transplant. 
Patient 2 
CB is a 22-year-old short prepubertal woman who 
was referred after she had undergone a complicated 
right hepatic lobe resection for hepatoma. At the age 
of 3 years she was noticed to have marked growth re-
tardation, hypophosphatemic ,vitamin D-resistant 
rickets, hepatomegaly and protein uria. A 24-h urine 
demonstrated a generalized amino aciduria with hy-
pertyrosyluria and p-hydroxyphenylaceticaciduria. 
Serial serum amino acid levels demonstrated 3-4-
fold increases in the levels of tyrosine and glutamic 
acid. She was treated with vitamin D, oral phosphate 
and a 6% sodium 4% potassium citrate solution and a 
tyrosine-deficient diet. At age 7 an angiogram dem-
onstrated a homogenous large liver with vascular tor-
tuosity consistant with cirrhosis but no tumor. At age 
21 years she was noted to have an even larger liver 
and angiography demonstrated a large tumor involv-
ing the right hepatic lobe. She had a preoperative al-
pha-fetoprotein level of 2 740 ng/ml, Fanconi's syn-
drome, and hepatic failure manifested as ascites, 
jaundice and a coagulopathy. Pertinent additional 
laboratory data are presented in Table 1. She under-
went orthotopic hepatic transplantation 20 January, 
1983 and she has been well and eating an unrestricted 
diet since, now 35 months after the transplant. 
Patient 3 
VO is a 4V4-year-old girl with tyrosinemia who was 
referred to us at 31 months of age because of hepatic 
failure manifested as coagulopathy, ascites and jaun-
dice. She had an abnormal alpha-fetoprotein of 4600 
ng/ml which declined to 1 100 ng/ml by 41 months of 
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TABLE I 
CLINICAL AND LABORATORY DATA OBTAINED PREOPERATIVELY OR FROM THE RECORD PRIOR TO REFER_ 
RAL 
Patient 
LT CB VO WT 
Cirrhosis + + + + 
Hepatoma + + + + 
Rickets + + + + 
Fanconi syndrome + + + 
Ascites + + + + 
Pro time ptlcontrol (s) 15/12 17111 17112 15111 
Platelet count (x 1000) 52 54 39 132 
WBC count (x 1000) 9.0 11.7 3.6 2.9 
Bilirubin (mgldl) 1.8 2.9 1.8 3.7 
Albumin (gld!) 3.8 2.8 3.6 2.9 
Hepatic fumarylacetoacetate hydrolase activity markedly decreased absent +a markedly decreased 
Urinary succinylacetate 
Urinary succinylacetoacetate 
Plasma tyrosine 
a Present but reduced. 
b Normal on dietary control (tyrosine-free diet). 
+ = increased. 
+ 
normalb 
age following intensive in hospital dietary manage-
ment. Additional pertinent laboratory data are 
shown in Table 1. On 15 January, 1984 she under-
went orthotopic hepatic transplantation at which 
time multiple hepatomas were found in the removed 
organ. The child is now well and eating an unre-
stricted diet 23 months post-transplantation. 
Patient 4 
WT is a 31/4-year-old female who was referred to 
us because of hepatic failure, Fanconi syndrome and 
the finding of an abnormal alpha-fetoprotein of 
13 560 ng/ml. Preoperative laboratory data are 
shown in Table 1. Orthotopic hepatic transplantation 
was performed on 28 May. 1984. Eighteen months 
absent absent 
normalb 
postoperatively, she is well and eats an unrestricted 
diet. 
Methods 
All plasma and urine samples collected preopera-
tively were obtained while the patients were on a strict 
tyrosine-free diet. All samples collected following 
transplantation were obtained while the patients 
were ingesting a standard hospital diet. Plasma sam-
ples for amino acid analysis were deproteinized using 
sulfosaJicyclic acid. Urine samples were adjusted to 
pH 2.2 with concentrated hydrochloric acid. The de-
proteinized samples were assayed on a Beckman 119 
( 
( 
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CL automatic amino acid analyzer. 
Urinary succinyl acetate and succinyl acetoacetate 
were assayed according to the method of Grenier et 
al. [6]. 
Other laboratory tests 
All standard blood and urinary chemistry studies 
were performed by the Clinical Pathology Laborato-
ry of the University of Pittsburgh School of Medicine, 
Department of Pathology either at Children's Hospi-
tal of Pittsburgh or at the Presbyterian-University 
Hospital. 
Follow-up 
Each patient described above and transplanted for 
tyrosinemia has been followed closely since trans-
j'lantation and is currently doing well without evi-
~dence of tyrosinemia or hepatic neoplasia. The three 
children are all growing normally and are entirely 
free of their former dietary restriction. The one adult 
has not grown or progressed further through puberty 
since transplantation. She is now 35 months post-
transplantation. She continues to demonstrate very 
mild delta aminolevulinic aciduria but not any of the 
TABLE 2 
-IS 
plasma findings of tyrosinemia (Table 2). 
Laboratory data obtained on these patients during 
the postoperative period and/or at last follow-up ex-
amination are shown in Table 2 and Figs. 1-4. 
Discussion 
The four patients herein reponed are of interest 
for several reasons: (1) they are the first 4 cases of ty-
rosinemia for which orthotopic hepatic transplanta-
tion has been applied and resulted in life outside hos-
pital on no dietary restriction; (2) all 4 patients had 
preoperative identifiable hepatomas present in the 
removed liver; (3) each patient is currently free of all 
evidence of hepatic cancer and has an undetectable 
alpha-fetoprotein level; (4) all abnormal serum ami-
no acid levels noted preoperatively have returned to 
normal following transplantation and have remained 
so since transplantation without dietary restriction; 
and (5) urinary amino acid excretion has been either 
normal or only minimally abnormal following suc-
cessful liver transplantation in patients 1 and 2, the 
only two so studied. However, patient 2 continues to 
LABORATORY DATA OBTAINED POSTOPERATIVELY OR IN FOLLOW-UP 
Patient 
LT CB VO WT 
Alpha-fetoprotein absent absent absent absent 
Protime ptlcontrol (s) 11111 11111 11111 11111 
Albumin (g/dl) 4.6 4.6 3.1 4.7 
Calcium (mg/dl) 10.6 10.2 9.2 10.1 
Phosphate (mg/dl) 3.9 4.1 3.1 4.2 
Urinary delta aminolevulinic acid (mg/dl) absent absent ND+ ND 
Succinyl acetone (mg/g creatinine) absent 18.00' ND ND 
p-Hydroxyphenyl acetic acid (mg/g creatinine) absent 29.56' ND ND 
Lactic acid (mg/g creatinine) absent 3.18' ND ND 
a Results from the McGill University Biomedical Mass Spectrometry Unit. 
ND = not done, + = increased. 
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Fig. 1. Fasting plasma (A) and 24-h urinary (B) amino acids be-
fore and after liver transplantation of Case 1. The shaded area 
represents the range of normal. The units on the ordinate are 
expressed in terms of units times the upper limit of normal (var-
iable range for each). 
excrete succinyl acetone suggesting that this metabo-
lite is still being produced at some non hepatic site 
(Table2). 
In such cases referral for possible orthotonic liver 
transplantation was initiated because of hepatic fail-
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Fig. 2. Fasting plasma (A) and 24-h urinary (B) amino acids be-
fore and after liver transplantation of Case 2_ The units as the. 
ordinate are expressed in terms of units times the upper limit of 
normal. 
ure either with or without a recognized hepatic can-
cer. These data demonstrate that the consequences 
of tyrosinemia such as abnormal plasma and urinary 
amino acid levels, growth failure, liver disease and 
hepatic neoplasms may be corrected as a result of 
successful orthotopic hepatic transplantation. 
Interestingly however, is the observation that de-
spite the fact of an apparent biochemical cure of tyro-
sinemia for 32 months following liver transplanta-
tion, the single adult studied has not grown as have 
the three children so treated and she has not pro-
gressed into puberty. This suggests that either her 
preexisting tyrosinemia has stunted her growth per-
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Fig. 3. Fasting plasma amino acids in Case 3 before and after 
liver transplantation. 
manently and has prevented her progression through 
puberty, or that other nonhepatic sites of her fum aryl 
acetoacetate hydrolase deficiency either are respon-
sible for, or regulate these processes. Her continued 
urinary excretion of small amounts of succinyl ace-
tone (less than V3 that observed prior to liver trans-
plantation) is consistent with this possibility. The spe-
cific location of these postulated nonhepatic sites are 
unknown at this time. In contrast to the findings in 
the one adult studied, the three children transplanted 
for tyrosinemia have all demonstrated normal linear 
growth postoperatively. The specific mechanisms re-
sponsible for this difference in response to successful 
liver transplantation for hereditary tyrosinemia be-
tween children and adults remains to be determined. 
These patients are also of interest in that their he-
patic neoplasms appear to be cured and apparently 
do not reoccur following successful orthotopic liver 
transplantation. This finding is quite different from 
that which occurs in adults with hepatoma and/or 
cholangiolar carcinoma not associated with metabol-
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Fig. 4. Fasting plasma amino acids in Case 4 before and after 
liver transplantation. 
ic liver disease who have been treated with transplan-
tation. Such individuals, despite successful transplan-
tation, redevelop or express their neoplasms in the 
transplanted liver and usually do so within 1 to 2 years 
following transpl~lKlltationK Our experience with he-
reditary tyrosinemia is quite different yet it is similar 
to our experience with other metabolic liver diseases 
of children 'which also are associated with hepatic 
neoplasia such as glycogen storage disease (n = 4) 
and antitrypsin deficiency (n = 25). Following suc-
cessful transplantation and resolution of the primary 
metabolic abnormality, hepatic neoplastic transfor-
mation has not been a problem in such children. 
In summary, we describe 4 cases of tyrosinemia, 
each with hepatic cancer and liver failure, treated 
successfully with orthotopic hepatic transplantation 
and cured of both their metabolic disorder and their 
hepatic neoplasm. Normal linear growth has oc-
curred following transplantation in the three children 
operated upon who were less than 5 years of age at 
the time of transplantation but has not occurred in 
the one adult with markedly retarded bone growth 
and sexual development due to prolonged disease (22 
years). 
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